GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (NAS:TCRT) » Definitions » Piotroski F-Score
中文

Alaunos Therapeutics (Alaunos Therapeutics) Piotroski F-Score

: 4 (As of Today)
View and export this data going back to 2005. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alaunos Therapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Alaunos Therapeutics's Piotroski F-Score or its related term are showing as below:

TCRT' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 4

During the past 13 years, the highest Piotroski F-Score of Alaunos Therapeutics was 4. The lowest was 1. And the median was 3.


Alaunos Therapeutics Piotroski F-Score Historical Data

The historical data trend for Alaunos Therapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.00 2.00 3.00 4.00 4.00

Alaunos Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 3.00 4.00

Competitive Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -10.048 + -8.773 + -8.476 + -7.843 = $-35.14 Mil.
Cash Flow from Operations was -9.381 + -7.002 + -6.374 + -7.385 = $-30.14 Mil.
Revenue was 0 + 0.004 + 0 + 0.001 = $0.01 Mil.
Gross Profit was 0 + 0.004 + 0 + 0.001 = $0.01 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(64.937 + 48.638 + 27.927 + 19.44 + 8.263) / 5 = $33.841 Mil.
Total Assets at the begining of this year (Dec22) was $64.94 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $8.26 Mil.
Total Current Liabilities was $1.96 Mil.
Net Income was -9.788 + -9.932 + -8.851 + -9.159 = $-37.73 Mil.

Revenue was 0 + 0 + 2.911 + 0.011 = $2.92 Mil.
Gross Profit was 0 + 0 + 2.911 + 0.011 = $2.92 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(94.865 + 84.991 + 73.931 + 67.344 + 64.937) / 5 = $77.2136 Mil.
Total Assets at the begining of last year (Dec21) was $94.87 Mil.
Long-Term Debt & Capital Lease Obligation was $2.19 Mil.
Total Current Assets was $53.80 Mil.
Total Current Liabilities was $24.17 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alaunos Therapeutics's current Net Income (TTM) was -35.14. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alaunos Therapeutics's current Cash Flow from Operations (TTM) was -30.14. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-35.14/64.937
=-0.54113987

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-37.73/94.865
=-0.39772308

Alaunos Therapeutics's return on assets of this year was -0.54113987. Alaunos Therapeutics's return on assets of last year was -0.39772308. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Alaunos Therapeutics's current Net Income (TTM) was -35.14. Alaunos Therapeutics's current Cash Flow from Operations (TTM) was -30.14. ==> -30.14 > -35.14 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/33.841
=0

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=2.188/77.2136
=0.02833698

Alaunos Therapeutics's gearing of this year was 0. Alaunos Therapeutics's gearing of last year was 0.02833698. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=8.261/1.956
=4.22341513

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=53.799/24.166
=2.22622693

Alaunos Therapeutics's current ratio of this year was 4.22341513. Alaunos Therapeutics's current ratio of last year was 2.22622693. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Alaunos Therapeutics's number of shares in issue this year was 16.013. Alaunos Therapeutics's number of shares in issue last year was 16.027. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.005/0.005
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.922/2.922
=1

Alaunos Therapeutics's gross margin of this year was 1. Alaunos Therapeutics's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0.005/64.937
=7.7E-5

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=2.922/94.865
=0.03080167

Alaunos Therapeutics's asset turnover of this year was 7.7E-5. Alaunos Therapeutics's asset turnover of last year was 0.03080167. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alaunos Therapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Alaunos Therapeutics  (NAS:TCRT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Alaunos Therapeutics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Alaunos Therapeutics (Alaunos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8030 El Rio Street, Houston, TX, USA, 77054
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.
Executives
Boyle Kevin S. Sr. director, officer: Chief Executive Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Robert Hofmeister director C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Jaime Vieser director ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129
Robert W Postma director 141 MECOX ROAD, WATER MILL NY 11976
Michael Wong officer: VP, Finance C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129
Abhishek K Srivastava officer: See Remarks C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Holger Weis director C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Christopher Bowden director 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Mary Thistle director C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Drew Deniger officer: VP, Research & Development C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054
Groot Eleanor De officer: EVP, Operations C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129
Melinda Lackey officer: Senior Vice President, Legal C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054
Heidi Hagen director AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105
Raffaele Baffa officer: Chief Medical Officer C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129